Aliases:This biomarker is also known as:
- follicle-stimulating hormone beta subunit,
- Follitropin subunit beta,
- Follitropin beta chain,
- follicle stimulating hormone, beta polypeptide,
- follitropin, beta chain,
Follicle stimulating hormone, a heterodimer glycoprotein of a common alpha chain and a unique beta chain which confers biological specificity to thyrotropin, lutropin, follitropin and gonadotropin, stimulates development of follicle and spermatogenesis in the reproductive organs. In conjunction with luteinizing hormone, follicle-stimulating hormone induces egg and sperm production. Defects in FSHB are a cause of isolated follicle-stimulating hormone deficiency. Selective follicle-stimulating hormone deficiency is an uncommon cause of infertility, producing amenorrhea and hypogonadism in women and oligo or azoospermia with normal testosterone levels in normally virilised men. FSHB belongs to the glycoprotein hormones subunit beta family. There are two transcript variants from alternative splicing that each encode the same protein.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
It is uncertain if FSH levels are related to ovarian cancer risk. Conclusions from different studies show conflicting results.
Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.
- Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk.
- A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.
- Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.